189 related articles for article (PubMed ID: 38698877)
1. Acid α-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review.
Schoser B; Raben N; Varfaj F; Walzer M; Toscano A
Mol Genet Metab Rep; 2024 Jun; 39():101085. PubMed ID: 38698877
[TBL] [Abstract][Full Text] [Related]
2. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan.
Fukuhara Y; Fuji N; Yamazaki N; Hirakiyama A; Kamioka T; Seo JH; Mashima R; Kosuga M; Okuyama T
Mol Genet Metab Rep; 2018 Mar; 14():3-9. PubMed ID: 29124014
[TBL] [Abstract][Full Text] [Related]
3. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
[TBL] [Abstract][Full Text] [Related]
4. Newborn screening for Pompe disease in Italy: Long-term results and future challenges.
Gragnaniello V; Pijnappel PWWM; Burlina AP; In 't Groen SLM; Gueraldi D; Cazzorla C; Maines E; Polo G; Salviati L; Di Salvo G; Burlina AB
Mol Genet Metab Rep; 2022 Dec; 33():100929. PubMed ID: 36310651
[TBL] [Abstract][Full Text] [Related]
5. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-mediated generation and characterization of a Gaa homozygous c.1935C>A (p.D645E) Pompe disease knock-in mouse model recapitulating human infantile onset-Pompe disease.
Kan SH; Huang JY; Harb J; Rha A; Dalton ND; Christensen C; Chan Y; Davis-Turak J; Neumann J; Wang RY
Sci Rep; 2022 Dec; 12(1):21576. PubMed ID: 36517654
[TBL] [Abstract][Full Text] [Related]
7. Genotype, phenotype and treatment outcomes of 17 Malaysian patients with infantile-onset Pompe disease and the identification of 3 novel GAA variants.
Chan MY; Jalil JA; Yakob Y; Wahab SAA; Ali EZ; Khalid MKNM; Leong HY; Chew HB; Sivabalakrishnan JB; Ngu LH
Orphanet J Rare Dis; 2023 Aug; 18(1):231. PubMed ID: 37542277
[TBL] [Abstract][Full Text] [Related]
8. Current status of newborn screening for Pompe disease in Japan.
Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Identification of Compound Heterozygous Mutations in a Patient With Late-Onset Glycogen Storage Disease Type II (Pompe Disease).
Zhang H; Chen J; Zhu Y; Ma X; Zhong W
Front Neurol; 2022; 13():839263. PubMed ID: 35386406
[TBL] [Abstract][Full Text] [Related]
10. Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease.
Lin N; Huang J; Violante S; Orsini JJ; Caggana M; Hughes EE; Stevens C; DiAntonio L; Chieh Liao H; Hong X; Ghomashchi F; Babu Kumar A; Zhou H; Kornreich R; Wasserstein M; Gelb MH; Yu C
Clin Chem; 2017 Apr; 63(4):842-851. PubMed ID: 28196920
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9 generated Pompe knock-in murine model exhibits early-onset hypertrophic cardiomyopathy and skeletal muscle weakness.
Huang JY; Kan SH; Sandfeld EK; Dalton ND; Rangel AD; Chan Y; Davis-Turak J; Neumann J; Wang RY
Sci Rep; 2020 Jun; 10(1):10321. PubMed ID: 32587263
[TBL] [Abstract][Full Text] [Related]
12. Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand.
Ngiwsara L; Wattanasirichaigoon D; Tim-Aroon T; Rojnueangnit K; Noojaroen S; Khongkraparn A; Sawangareetrakul P; Ketudat-Cairns JR; Charoenwattanasatien R; Champattanachai V; Kuptanon C; Pangkanon S; Svasti J
BMC Med Genet; 2019 Sep; 20(1):156. PubMed ID: 31510962
[TBL] [Abstract][Full Text] [Related]
13. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
[TBL] [Abstract][Full Text] [Related]
14. Pompe disease ascertained through The Lantern Project, 2018-2021: Next-generation sequencing and enzymatic testing to overcome obstacles to diagnosis.
Sniderman King L; Pan Y; Nallamilli BRR; Hegde M; Jagannathan L; Ramachander V; Lucas A; Markind J; Colzani R
Mol Genet Metab; 2023 May; 139(1):107565. PubMed ID: 37087815
[TBL] [Abstract][Full Text] [Related]
15. Clinical manifestations and acid alpha-glucosidase mutation characterisation of a cohort of patients with late-onset Pompe disease in eastern China.
Zhao HH; Ma Z; Ying ZX; Niu FN; Luo MT; Wang Z; Cheng X; Zhang QQ; Niu Q
Ann Transl Med; 2021 Dec; 9(24):1803. PubMed ID: 35071497
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
[TBL] [Abstract][Full Text] [Related]
17. Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease.
Wang J; Zhou CJ; Khodabukus A; Tran S; Han SO; Carlson AL; Madden L; Kishnani PS; Koeberl DD; Bursac N
Commun Biol; 2021 May; 4(1):524. PubMed ID: 33953320
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.
Khanna R; Powe AC; Lun Y; Soska R; Feng J; Dhulipala R; Frascella M; Garcia A; Pellegrino LJ; Xu S; Brignol N; Toth MJ; Do HV; Lockhart DJ; Wustman BA; Valenzano KJ
PLoS One; 2014; 9(7):e102092. PubMed ID: 25036864
[TBL] [Abstract][Full Text] [Related]
19. [GAA gene variants and genotype-phenotype correlations in patients with glycogen storage disease type Ⅱ].
Huang YL; Sheng HY; Jia XF; Su XY; Zhao XY; Xie T; Tang CF; Liu SC; Li XZ; Zhang W; Mei HF; Zeng CH; Liu L
Zhonghua Er Ke Za Zhi; 2021 Mar; 59(3):189-194. PubMed ID: 33657692
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]